Humanized Monoclonal Antibody Specific to the Extracellular Domain of PSMA: Dose Escalation Trial in Patients with Prostate Cancer

摘要

Prostate specific membrane antigen (PSMA) is the single most well- established, highly restricted prostate epithelial cell membrane antigen expressed by virtually all prostate cancers. PSMA is an ideal target for developing radio labeled monoclonal antibodies (mAbs) for radioimmunotherapy (RIT) of prostate cancer. J591 mAb binds with very high affinity to the extra- cellular domain of PSMA and binds to viable tumor cells. We have previously submitted the final report of the Phase I of the Idea development Award in November 2000.